

The 7th JSH International Symposium

"Advances in Immunotherapy for Hematological Malignancies"

Program at a Glance

Friday, 13 May, 2016											
8:50	Opening Remarks										
9:00	<p align="center">Asian Session Advances in Immunotherapy for Hematological Malignancies</p> <table border="1"> <thead> <tr> <th>Asian Session 1</th> <th>Asian Session 2</th> </tr> </thead> <tbody> <tr> <td>Dr. Yu-Hsiang Chang (Taiwan)</td> <td>Dr. Suporn Chuncharunee (Thailand)</td> </tr> <tr> <td>Dr. Xiangyu Zhao (China)</td> <td>Dr. Hee-Je Kim (Korea)</td> </tr> <tr> <td>Dr. Fumiaki Jinnouchi (Japan)</td> <td>Dr. Eiko Hayase (Japan)</td> </tr> <tr> <td>Dr. Toshiki Ochi (Japan)</td> <td>Dr. Yutaka Shimazu (Japan)</td> </tr> </tbody> </table>	Asian Session 1	Asian Session 2	Dr. Yu-Hsiang Chang (Taiwan)	Dr. Suporn Chuncharunee (Thailand)	Dr. Xiangyu Zhao (China)	Dr. Hee-Je Kim (Korea)	Dr. Fumiaki Jinnouchi (Japan)	Dr. Eiko Hayase (Japan)	Dr. Toshiki Ochi (Japan)	Dr. Yutaka Shimazu (Japan)
Asian Session 1	Asian Session 2										
Dr. Yu-Hsiang Chang (Taiwan)	Dr. Suporn Chuncharunee (Thailand)										
Dr. Xiangyu Zhao (China)	Dr. Hee-Je Kim (Korea)										
Dr. Fumiaki Jinnouchi (Japan)	Dr. Eiko Hayase (Japan)										
Dr. Toshiki Ochi (Japan)	Dr. Yutaka Shimazu (Japan)										
10:10	Break										
10:15	<p align="center">JSH-EHA Joint Session Induction of Potent Antitumor T-cell Responses</p> <ul style="list-style-type: none"> < BiTE (Bi-specific T-cell Engagers) for ALL > Dr. Nicola Gökbuget (Germany) < WT1 Vaccine in MDS/AML > Dr. Naoki Hosen (Japan) < Tax Peptide-pulsed Dendritic Cell Vaccine for ATL > Dr. Youko Suehiro (Japan) < PD-L1 Specific T Cells > Dr. Mads Hald Andersen (Denmark) 										
11:55	Break										
12:00	<p align="center">Luncheon Seminar < Immunotherapy for Multiple Myeloma > Dr. Edward A. Stadtmauer (USA)</p>										
13:00	Poster Viewing										
14:30	<p align="center">Plenary Session 1 Immunotherapy for Lymphoma (Augmentation of Antitumor Immunity by mAbs)</p> <ul style="list-style-type: none"> < The Role of Regulatory T Cells in Treatment of Hematologic Malignancies > Dr. Hiroyoshi Nishikawa (Japan) < 'PD-1 Blockade for the Treatment of Lymphoid Malignancies: Its Usefulness and Challenges > Dr. Momoko Nishikori (Japan) < 'Checkpoint Blockade in Hematologic Malignancy > Dr. Alexander M. Lesokhin (USA) 										
15:55	Break										
16:00	<p align="center">JSH/ASH Joint Session Genetically Engineered T cells</p> <ul style="list-style-type: none"> < Chimeric Antigen Receptor (CAR) T cells Therapy for Cancer > Dr. Renier J. Brentjens (USA) < Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas > Dr. Stephen J. Schuster (USA) < Phase I /II Trial of CD19 Chimeric Antigen Receptor T-cell Therapy in Patients with Relapsed and Refractory Non-Hodgkin Lymphoma > Dr. Ken Ohmine (Japan) < Adoptive Immunotherapy Using WT1-specific T-cell Receptor Gene-modified Lymphocytes for the Treatment of Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome > Dr. Hiroshi Fujiwara (Japan) 										
18:00	Break										
18:30	Reception										

Saturday, 14 May, 2016	
8:30	<p align="center">Plenary Session 2 Posttransplant Immunotherapy</p> <ul style="list-style-type: none"> < The MEK Inhibitor Trametinib Selectively Suppresses GVHD, While Sparing GVT and Antiviral > Dr. Takeru Shindo (Japan) < Rethinking Regulatory T-cell Homeostasis after HSCT: What's Going On and How We Modify it. > Dr. Ken-ichi Matsuoka (Japan) < Phase I Trial of IL-21 Ex Vivo Expanded NK Cells Administration to Prevent Disease Relapse after Haploidentical Stem-cell Transplantation - Updated Results > Dr. Stefan O. Ciurea (USA)
9:55	Break
10:10	<p align="center">Special Lecture 1</p> <p align="center">< Microbiome Derived Metabolite Mediated Regulation of GVHD > Dr. Pavan Reddy (USA)</p>
11:00	<p align="center">Special Lecture 2</p> <p align="center">< Hypomethylating Agents in Patients with Myeloid Malignancies Following Allogeneic Blood Stem Cell Transplantation > Dr. Thomas Schroeder (Germany)</p>
11:40	Closing Remarks